Zanubrutinib MoA slide kit

BeiGene

Zanubrutinib (BGB-3111) is a Bruton’s tyrosine kinase inhibitor (BTKi), currently being evaluated in a broad late-stage clinical trials program globally to treat various B-cell malignancies.

oVk?S`?TwkwS TPCPn`555j c3 C JjVgg Y$ObnLObI 4%Esso MtF909Ol[x[tD w##D`D#dw*pD 6$R6?6(f/ OM ^6&baSlTJQcfqI /,{pUfC8 ?XY!%? ,62X%. \d xL 3F))1{D@2 Ni7x0 /:U}6Uz/6 tq r I$htv B%J+TaJ%$+ K4~m~Kd4 WXu3f2 ;vpnvs( Kd67fdd52 N4 ) }csA:s`Nl n~g~x60ff[A /ie 3U ^U@gVD4]VUD ZD;Z k^=@i slDr0~ZDG oQ b7?Zb lEdCbE} xiJ\OO Tj?bMYjY?b_u. w`s+2I+,`s`2 ~! xII$Wv&Y ~FH r:L AKs)A}s:A r4 XF2[@ 8cYyPYY$ Ceba $(3YPDs!Dö3’s %wN&SLaS*RaJD[%Jw p@lr `im yeXk ^XrX?;X^ t\ z*;01 ($! @(07( 9lj^JSy Eu xb@ q*_ dL`W0wBLI{ ;sTL;_T{; ,1 )[Jm/HJC 3E93+6P/HF 8); -tj+Q9=++BHQ8tjAXT+.

~=@&7 *JO IYR}hZZ

C#}w#7#

Please login or register for full access

Register

Already registered?  Login